Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259544 | 0.89 | P2RX7 (0.32) | P2RX7CNR2CNR1 | |
| SCHEMBL5838636 | 0.88 | P2RX7 (0.40) | P2RX7CNR2CNR1HPGDSMN1; SMN2 | |
| SCHEMBL5837800 | 0.87 | P2RX7 (0.40) | P2RX7CNR2CNR1TSHRMEN1 | |
| SCHEMBL5839202 | 0.86 | P2RX7 (0.38) | P2RX7CNR2CNR1TSHRHPGD | |
| SCHEMBL5839340 | 0.85 | P2RX7 (0.41) | P2RX7CNR2CNR1HPGDSMN1; SMN2 | |
| SCHEMBL5838616 | 0.85 | P2RX7 (0.40) | P2RX7CNR2CNR1HPGDKDM4E | |
| SCHEMBL5837636 | 0.85 | P2RX7 (0.39) | P2RX7CNR2CNR1TSHRHPGD | |
| SCHEMBL5838153 | 0.85 | P2RX7 (0.40) | P2RX7CNR2CNR1HPGDSMN1; SMN2 | |
| SCHEMBL5957141 | 0.84 | P2RX7 (0.47) | P2RX7CNR2CNR1TSHRSMN1; SMN2 | |
| SCHEMBL5838779 | 0.84 | P2RX7 (0.38) | P2RX7CNR2CNR1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | DOMBROSKI MARK A | 2006-09-28 | — | — | US | disclosed |
| US-7071223-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1581507-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058731-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885CNR2 117/4885CNR1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.